47 completed, 27 recruiting, 21 terminated, 13 active not recruiting. 87 Phase 2, 63 Phase 1, 2 Early Phase 1, 2 Not applicable, 2 Phase 3.
Follow azacytidine: new trials by email Literature Review of azacytidine trials Research Report on azacytidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-07-09 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-11-01 | 2026-10-27 |
| FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 9 | 2026-10-15 | 2026-09-17 |
| Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-21 | 2026-10-05 |
| Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms Pacritinib, Decitabine, Decitabine and Cedazuridine - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | University of Washington | 27 | 2026-03-02 | 2026-08-19 |
| Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent Azacitidine, Olutasidenib - Acute Myeloid Leukemia | Phase 2 | Recruiting | University of California, Davis | 28 | 2025-12-17 | 2026-10-27 |
| A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 12 | 2025-07-30 | 2026-09-29 |
| Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 20 | 2025-04-25 | 2026-10-20 |
| Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Venetoclax, Q702 - Acute Myeloid Leukemia | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 17 | 2025-02-12 | 2026-05-29 |
| AZA Combined with R-GemOx for Elderly DLBCL Patients azacytidine, R-GemOx - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 80 | 2025-02-01 | 2025-01-16 |
| Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | City of Hope Medical Center | 43 | 2025-01-28 | 2026-07-16 |
| Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Monocytic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 40 | 2025-01-03 | 2026-09-16 |
| A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias Ziftomenib, Venetoclax, Azacitidine - Refractory Acute Leukemia, Pediatric Relapsed | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 22 | 2024-12-27 | 2026-09-03 |
| Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 1 | Suspended | National Cancer Institute (NCI) | 45 | 2024-12-18 | 2026-08-25 |
| Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Withdrawn | City of Hope Medical Center | 2024-10-09 | 2024-09-19 | |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 147 | 2024-09-27 | 2026-10-27 |
| Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 335 | 2024-09-25 | 2026-10-27 |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2024-09-13 | 2026-10-26 |
Showing 20 of 126. Sign in to see all of them.
Leukemia, Myeloid, Acute (76) · Myelodysplastic Syndromes (41) · Leukemia, Myelomonocytic, Chronic (23) · Leukemia (16) · Myeloproliferative Disorders (10) · Carcinoma, Non-Small-Cell Lung (7) · Leukemia, Erythroblastic, Acute (7) · Leukemia, Megakaryoblastic, Acute (7) · Leukemia, Monocytic, Acute (7) · Leukemia, Myelomonocytic, Acute (7) · Congenital Abnormalities (5) · Leukemia, Biphenotypic, Acute (5) · Myelodysplastic-Myeloproliferative Diseases (5) · Recurrence (5) · Anemia, Refractory, with Excess of Blasts (4)
M.D. Anderson Cancer Center (41) · National Cancer Institute (NCI) (33) · City of Hope Medical Center (5) · Fred Hutchinson Cancer Center (4) · OHSU Knight Cancer Institute (3) · Uma Borate (3) · Brian Jonas (2) · University of Southern California (2) · Weill Medical College of Cornell University (2) · Albert Einstein College of Medicine (1) · Alice Mims (1) · Arog Pharmaceuticals, Inc. (1) · Assistance Publique Hopitaux De Marseille (1) · Benjamin Tomlinson (1) · Brenda Cooper, MD (1)
United States (111) · Canada (7) · Puerto Rico (5) · China (4) · Australia (2) · Belgium (1) · France (1) · Hong Kong (1) · Italy (1) · Japan (1) · Saudi Arabia (1) · Singapore (1) · Switzerland (1)
Guillermo Garcia-Manero (5) · Brian A Jonas (3) · Courtney DiNardo (3) · Naval Daver (3) · Nicholas Short (3) · Bart Scott (2) · Courtney DiNardo, MD (2) · Curtis A Lachowiez (2) · David McCall, MD (2) · David S Schrump, M.D. (2) · Guillermo Garcia-Manero, MD (2) · Guillermo M Bravo (2) · Naval Daver, MD (2) · Naval G Daver (2) · Peter Martin, MD (2)
PMID 24583822, PMID 26577691, PMID 18042004, PMID 19546476, PMID 19652201, PMID 22586682, PMID 23265768, PMID 23547838, PMID 24092933, PMID 24142996, PMID 29134664, PMID 29339403, PMID 29618479, PMID 30001986, PMID 30028037, PMID 30185431, PMID 31212080, PMID 32074275, PMID 33636454, PMID 34889407, PMID 34980577, PMID 35078972, PMID 35442137, PMID 35704787, PMID 35973199, PMID 36063832, PMID 36841758, PMID 36902217, PMID 37422688, PMID 38277619, PMID 38391202, PMID 38548404, PMID 38572562, PMID 38744144, PMID 38775157, PMID 38867582, PMID 39300320, PMID 40073835, PMID 40513054, PMID 40932107, PMID 42007254, PMID 42035228, PMID 42200455, PMID 42304430
P30CA006973 (6), P30CA016672 (6), P30CA033572 (5), U10CA180820 (4), U10CA180888 (4), P30CA093373 (3), U01CA070095 (3), N01CM00038 (2), N01CM00099 (2), P30CA013330 (2), P30CA015083 (2), P30CA015704 (2), P30CA016058 (2), U10CA032102 (2), UM1CA186691 (2)